Share

Quotes

"We're pleased to see our initial talks at CPHI have progressed to a new partnership. Nabih Nabulsi Drugstores possesses the right local expertise to launch our products into pharmacies and drugstores effectively. Their market dominance and well-established relationships in Jordan make them the ideal partner for our global expansion efforts."
Lone Henriksen, CEO of CS MEDICA A/S
"The reason for choosing CANNSEN® as a new treatment option in our market is due to its innovation and uniqueness. Being one of the first in the market to combine the proven track records and legislation of medical devices with the therapeutic benefits of CBD makes it a groundbreaking addition to our portfolio. As a market leader, we must continually seek out innovative products to expand and grow the market. CANNASEN® represents a significant step in this direction, offering a unique value proposition that we believe will resonate with our customers."
Dr. Nabulsi, the owner of Nabih Nabulsi Drugstores
"The approval of this patent, our third within a year, is a commitment to our focused approach towards healthcare innovation. Importantly, we are progressing with several more treatments pending patent approval, validating our purpose to deliver innovative healthcare solutions to 2- and 4-legged patients globally."
Lone Henriksen, CEO and founder of CS MEDICA
"Being a first-mover combining science with the therapeutical benefits of cannabinoids, under strict compliance and regulatory rules holds challenges, but this is a recognition for us to continue focusing on providing efficient, over-the-counter alternative treatments to the market."
Lone Henriksen, CEO and founder of CS MEDICA
We are proud that we have managed to adapt and remain compliant and relevant for the market. It's a testament to our team's resilience and commitment. The registration of the CANNASEN Pain Patch, the first substance-based medical device with Cannabis Sativa L in Australia, marks a significant milestone for us. It demonstrates our ability to navigate complex regulatory landscapes.
Lone Henriksen, CEO of CS MEDICA
"We are excited to have partnered with CANNORDIC, their understanding of not only adapting to the registration process but also adjusting the brand to meet our local market requirements while staying brand consistent is commendable. Their products are effective, safe and of high quality, manufactured in Europe." 
Jakob Gajadhar, Director of Icon Medipharm
"Receiving FDA notification approval for these eight products is not just a triumph for us, but a testament to the research and dedication behind our products. The U.S. market is pivotal in the cannabis sector, but yet a grey market for safety and proof of concept, especially for different functions of the cannabis than traditional ones. Hence, our entry through this approval marks a significant milestone in our global expansion strategy. We are eager to bring our innovative treatments to American consumers and are confident that our presence on the market will be a game-changer in how people experience our products and company.".
CS MEDICA's CEO, Lone Henriksen:
I'm very proud to confirm that a second member of our portfolio comprising 7 different patent families has been granted. Even though I have a long track record in the pharma industry, it is always different and thrilling when it is your own 'hero' that is considered patentable.
Inventor and biochemist Lone Henriksen, CEO and co-founder, CS MEDICA A/S
The Nasal Protect Gel patent and pending patent applications represent a significant competitive advantage for CS MEDICA, solidifying the Company's position as a challenger and innovator in the field of nasal healthcare solutions. This recognition further strengthens the Company's intellectual property portfolio and growth plans, and particularly the ambition to innovate the healthcare industry.
Inventor and biochemist Lone Henriksen, CEO and co-founder, CS MEDICA A/S
One of the things to secure when building a global business is trademarks. CS MEDICA has always been active in filing patents to secure the future of our products, but we also see the value of securing our brands with trademark registration. This is an additional important step we are taking in our global sales strategy.
Lone Henriksen, CEO CS MEDICA
Securing Indian FDA approval for these cosmetic products is just the beginning of our journey in India. We're poised to introduce CS MEDICA's medical innovations, set to redefine the industry, pioneer innovation, and enhance well-being throughout India.
Kamlesh Vora, Managing Director at Cannordic India Pvt Ltd
This credit facility exemplifies Danske Bank's commitment to supporting CS MEDICA's growth and success. It provides us with the financial flexibility we need to operate effectively and finally have the means to pay for our production and expedite product delivery, allowing us to meet our customers' order demands in due time.
Lone Henriksen, CEO at CS MEDICA
Our market research in Asia, has revealed that the Malaysian FDA approved the cannabis prescription medicine Sativex in 2014. This significantly streamlines the registration process for our six medical devices, which we expect to classify as Class 1 & 2, aligning with Malaysian FDA regulations. In light of CS MEDICA's financial situation, we are pleased to cover all registration costs. We anticipate a swift market entry in Malaysia and a successful venture into the Asian market.
Jason, Managing Director, Rongshi Medica Co. Ltd.
Following successful joint participation with our Joint Venture partner Rongshi Medica at CPHI in Guangzhou, we are delighted to embark on the registration process in Malaysia. This marks a significant step forward in our partnership and underscores the immense potential we see in our cooperation within the Asian market.
Lone Henriksen, CEO at CS MEDICA
We are thrilled to engage in productive interactions, meaningful discussions, and the establishment of strategic alliances at the current CPHI & PMEC China 2023 event. The engagement and will to win the Chinese market from CS MEDICA shows us that we collectively steer the course of healthcare's future in China and across the vast Asian market.
Jason, Managing Director, RongShi MEDICA
The continued success of our Joint Venture emphasizes the persistent commitment of CS MEDICA and RongShi to drive the future of healthcare in China and beyond. We eagerly anticipate furthering our accomplishments, cultivating fresh partnerships, and maintaining our position as pioneers in pharmaceutical innovation.
Lone Henriksen, CEO at CS MEDICA and Board member at RongShi MEDICA
I’m very proud to confirm that the first member of our portfolio comprising 7 different patent families is granted. Even though I have a long track record in the pharma industry, it is different and exciting when it is your own ‘hero’ that is considered patentable.
Inventor Lone Henriksen, CEO and co-founder, CS MEDICA A/S
The Nasal Night Spray patent and pending patent applications represent a significant competitive advantage for CS MEDICA, solidifying the Company's position as a challenger and innovator in the field of nasal healthcare solutions. This recognition further strengthens the Company's intellectual property portfolio and growth plans, but particularly the ambition to innovate the healthcare industry
Inventor Lone Henriksen, CEO and co-founder, CS MEDICA A/S
We are very pleased to announce the establishment of our Indian company. This move allows us to bring our innovative CBD products to the Indian market and cater to the evolving needs of consumers.
Kamlesh Vora, Local Managing Director
We see great growth potential in India, especially considering the country's strength within the pharmaceutical industry. This expansion will enable us to serve our customers better, being individuals with symptoms and local strategic business partners, and aim for sustainable growth in the Indian pharmaceutical sector.
Lone Henriksen, Overseas Managing Director, and CEO of CS MEDICA A/S
We are proud to be chosen as an own-label supplier to a strong local player in the Spanish and Portuguese Healthcare market. This allows us to expand further into Spain and Portugal with our unique products in the Pain category. As part of the own-label partnership, we cannot disclose the company name, but can highlight the company has 185 years of experience and growth and is one of the leading Natural Consumer Healthcare companies in Europe. We look forward to the collaboration.
Lone Henriksen, CEO & Co-founder CS MEDICA A/S
We are proud to announce CS MEDICA signed with the Notified Body in the Netherlands, which can help us secure the transition to MDR and is to issue the CE MDR certificate for the products. This achievement showcases our dedication to maintaining the utmost quality and safety in our products, while also demonstrating our commitment to meeting the rigorous requirements set forth by the New MDR regulation.
Lone Henriksen, CEO & Co-Founder, CS MEDICA
It is further a true cornerstone for our company’s global growth plans, especially partnering with Big Pharma players and positioning our company closer to the medicine industry long-term.
Lone Henriksen, CEO & Co-Founder, CS MEDICA
It is very positive to witness the effect from our improved processes which not only benefits our customers, but also CS MEDICA's cash flow
Lone Henriksen, CEO CS MEDICA
We are proud to announce our presence in APAC (Asia Pacific) is growing with strong partners as this target region is one of the fastest growing within CBD and alternative OTC products. Furthermore, we are pleased that the European markets are actively requesting to distribute our branded products.
Lone Henriksen, CEO CS MEDICA
We at CS MEDICA are thrilled and proud to have achieved the distinction of being the first to introduce an OTC product with CBD to the Israeli market. This milestone is a testament to our commitment to developing innovative and effective Medical products under the CANNASEN® brand, and we look forward to bringing the full range of our CANNASEN® products to patients in Israel with the help of our partner, Forbe Healthcare.
Lone Henriksen, CEO CS MEDICA
Vitafoods Europe last year was a huge success and helped us grow our customer base and gain awareness of our CE-marked medical devices with CBD. We have expanded our presence to 15 markets the last year and expect to find more local partners to collaborate with in the coming days. Fortunately, this year we have again a product placed at Vitafoods Europe NEW PRODUCT section, our new Wound gel. Finally, we are proud to launch our new harmonized packaging design and reveal our upcoming launches on VET and SPORT segments at the booth.
Lone Henriksen, CEO of CANNORDIC & CS MEDICA
By participating in a trade show, we aim to reach a wider audience, raise awareness of our brand, and connect with new customers. We additionally expect to generate leads by showcasing our products and attracting potential customers. Lastly, attending trade shows can provide valuable market insights, allowing us to keep up-to-date with industry trends and competitors.
Lone Henriksen, CEO of CANNORDIC & CS MEDICA
We are thrilled with the positive results of this clinical trial, which further validates the efficacy and safety of Nasal Protect Gel in treating hay fever/allergic rhinitis.
Lone Henriksen, CEO of CS MEDICA
We believe that Nasal Protect Gel has tremendous potential to improve the quality of life for millions of individuals suffering from chronic rhinitis, and we are excited about the future of this product in the market.
Lone Henriksen, CEO of CS MEDICA
We are thrilled to introduce our CANNASEN products to the Indian market, which presents significant opportunities for our company. With the appointment of Kamlesh Vora as the Managing Director of CANNORDIC India Pvt Ltd, we have a seasoned leader who brings a wealth of experience to guide us through the complex regulatory landscape and successfully launch our products.
Lone Henriksen, CEO at CS MEDICA
As the Managing Director of CS MEDICA's Indian subsidiary, I am thrilled to announce our expansion into the Indian market. With our expertise in MedTech and CBD-based medical devices, we are excited to bring our innovative products to India and provide safe and effective treatment options for patients suffering from autoimmune and stress-related disorders. Our commitment to combining science and nature aligns perfectly with the needs of the Indian market, and we are eager to submit our applications for registration with CDSCO[1]. We look forward to making a positive impact on healthcare in India and creating new opportunities for patients in need.
Kamlesh Vora, Managing Director of CANNORDIC India Pvt Ltd.
We are thrilled with the positive results of this clinical trial, which confirms the efficacy, safety, and tolerability of the CANNASEN® Pain Patch in managing pain. This is a significant milestone for our company, and it truly supports our go-to-market plans for our innovative and effective pain management solution.
Lone Henriksen, CEO & CSO of CS MEDICA
Our successful, clinically proven, and documented results will help us speed up our go-to-market plans and begin taking market shares of a growing market. It also means we will look into a broader range of patches to match the demand for pain relief with CBD benefits.
Lone Henriksen, CEO & CSO of CS MEDICA
With this JV agreement and business license in China we are stepping into a whole new area of the CS MEDICA. Together with RongShi we now have the necessary capacity in CS MEDICA to penetrate the Asian market with our CANNASEN®CBD medical products. I am truly looking forward to our cooperating with Mr. Gao (Jason), and with Guo Longlong (Harry), our Asian Director, who will be responsible for the Asian market. I am sure we together will reach new heights with the JV as well as for CS MEDICA
Lone Henriksen, CEO CS MEDICA
RongShi not only invests CS MEDICA in Denmark, but also setup “Rongshi Medica (Ordos) Co., Ltd.” in my hometown Erdos because I, my partner Mr. Xue and my team believe that the medical cannabis and CBD medical products will have a huge potential in the following 5 years in the market of China and other Asian countries. Today in China hemp growing cover more than 50% of the global production of Hemp, and many extraction companies produces CBD using CO2 extraction technology. These kinds of companies are located in Yunnan province and Heilongjiang Province, China. With the Joint Venture we differentiate from these hemp growers and extraction companies. We only focus on the CBD medical devices products approved by local FDA. This will reduce the risk for “Rongshi Medica (Ordos) Co., Ltd.” and CS MEDICA. We believe our cooperation will be success to reach the win-win
Mr Gao(Jason) General Manager of Rongshi Medica (Ordos) Co., Ltd.
We believe that RongShi & CS MEDICA is a very good match, as RongShi provide funding, investment, local network & business knowledge in Asia, whereas CS MEDICA provides the technology, quality assurance & registrations. We look forward to our very first exhibition at the Global pharmaceutical exhibition CPHI in Tokoy Japan April 19 – 21, 2023, where Rongshi Medica (Ordos) Co., Ltd. Participate together with CS MEDICA.”
Lone Henriksen, CEO CS MEDICA & Board Member of Rongshi Medica (Ordos) Co., Ltd.
The negotiation with RongShi regarding an investment and Joint Venture in China has been a long and complicated process. Firstly, caused by our required share price with a premium of 454%, but also the cultural difference between Denmark & China and COVID-19 have had a huge impact. But as both parties had a true interest in this agreement, we finally found a solution acceptable for both parties.
Gitte Lund Henriksen, CFO CS MEDICA A/S
We are so happy and proud of these agreements as this new funding of 60 MDKK, is the most important agreement CS MEDICA has made, and this without any expensive financial advisors involved, meaning the total funding is received by CS MEDICA. Mr. Guo (Harry), Asian Director in CS MEDICA has been involved in the process from the very beginning and have been a great help for CS MEDICA recognizing and handling the culture difference and importance of the face-to-face meeting doing the business with Chinese company. This is why we decided to visit RongShi Hi-Tech Co. Ltd in March after the failed negotiation in January. Now CS MEDICA has succeeded entering into a final agreement with Inner Mongolia RongShi Hi-Tech Co., Ltd regarding a total equity investment of DKK 60M in CS MEDICA at a share price of DKK 28.13
Gitte Henriksen, CFO CS MEDICA
CS MEDICA and RongShi have 100% confidence to receive the registration approval from China National Medical Products Administration within 3 months if classified as Class I Medical Device. If classified as Class II Medical Device, we will receive the registration approval within 12 months. Even the worst scenario is we can’t receive the registration approval within 12 months from China National Medical Products Administration. Our JV will produce our brand products CANNASEN® CBD in our JV production line and apply for the registration approval from the Inner Mongolia Medical Products Administration. This will be easy to receive the registration approval because JV is a domestic company to the Inner Mongolia government and Inner Mongolia Medical Products Administration.
Mr. Gao (Jason), Legal owner and General Manager, RongShi,
We chose to contact CS Medica as we see great advantages in being a First-Mover into the Asian market and the natural synergies between their medical technology platform and our production capacity and distribution network. We have recently noticed that the market in Asia has matured and is now ready for CBD-products, and we are at the end of our Due Diligence and looking forward to taking further steps ahead. Our ambition is to be a strong long-term partner.
Inner Mongolia Rong Shi Hi-Tech Co., Ltd
I really look forward to discussing the process and joint venture further with Rong Shi when they visit us later the year.
Lone Henriksen, CS MEDICA
"We are happy to announce that CS MEDICA is closing the year with 10,6M DKK in revenue, and we are proud of the strong partnerships we have developed in the last months. We have moved from being an R&D to a commercialized company, now listed in most pharmacies in DK, on Amazon, and we have signed with distributors in Israel, Hong Kong, Slovenia, Croatia, and Serbia to market our Cannasen® brand. The latest distribution partner we have teamed up with is Alliance Healthcare Romania, part of the Alliance Healthcare, one of the largest wholesalers in Europe, supplying more than 115,000 pharmacies, doctors, and health centers in 13 countries. This order includes our full Cannasen® portfolio incl. the new Wound Gel." 
Lone Henriksen, CEO CS MEDICA
We are happy to have this huge investment interest from the Asian market, and Inner Mongolia Rong Shi Hi-Tech Co. as well as us are aiming for a quick due diligence as we hope to get into operation as soon as possible
Lone Henriksen, CEO CS MEDICA
CS MEDICA are happy to announce that we found a strong partner, with the right strategy in place, to kick start sales in several Balkan countries. We see this as an opportunity to step into a region, not easily accessible without the know-how in the market. Also, this as an option to further develop the Balkan and Eastern EU presence in near future.
Lone Henriksen, CEO CS MEDICA
Ampilio has done a great job helping us launch on both the Swedish and German Amazon; however, we experience products containing CBD need a different strategy and communication. The speed to market has been too slow; consequently, we agreed to move our partnership to Incubeta Maze-One, a preferred Amazon partner like Ampilio, but who is familiar working with CBD brands on Amazon.
Heidi Ahlefeldt-Laurvig, CMO & CGO, CS MEDICA A/S
We work with several Nordic brands within personal care, including CBD-based products, where we see an increasing sales potential in Europe. Selling CBD-based products on Amazon comes with certain compliance demands that require special solutions and communication tactics. We look forward to working with CS MEDICA to build and grow Amazon as a sales channel.
Ulrik Grevenkop-Castenskiold, Managing Director, Incubeta Maze-One Nordic
We are looking forward to starting the process preparing the CS MEDICA’s shares to the Main Market in Denmark.
Lone Henriksen, CEO and founder of CS MEDICA
We are happy we launched at Spotlight as a nano/microcap company in an early growth phase, and the support has been outstanding. However, as we have finalized the main clinical trials, we are rapidly reaching international territories with our finished, registered products plus the technology and science behind the formulas and CBD know-how, allowing us to reach further segments. Combined with the fact we have a first mover advantage, being ahead of the competition on registrations from MDD to MDR, we need to capitalize now. Hence, we need to prepare for the next growth phase, and have been recommended to start the process of moving to the Main Market
Lone Henriksen, CEO and founder of CS MEDICA
Alsitan has had a very successful market reception of the arthritis gel in the German market and is now expanding their portfolio with another white label CANNASEN product - a new advanced arthritis pain gel. Together with Alsitan, who are experts in their field, this order gives us a unique opportunity to better match our product portfolio to the market dynamics. We see this not only as proof of concept, but also proof of business.
Lone Henriksen, CEO CS MEDICA